Ocugen, Inc. (NASDAQ:OCGN) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts give Ocugen an average rating of Moderate Buy (four buys, one sell) with a consensus 1‑year price target of $9.75 and recent targets roughly in the $7–$12 range.
• Shares trade near $1.76 with a $577M market cap and a 12‑month range of $0.64–$2.73; the company reported negative EPS, missed revenue expectations, and shows weak profitability alongside a high debt‑to‑equity ratio (8.04).
• Institutional investors own about 10.27% of the stock, and several hedge funds modestly increased their stakes in recent quarters.

Shares of Ocugen, Inc. (NASDAQ:OCGN - Get Free Report) have received an average rating of "Moderate Buy" from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $9.75.

Several equities analysts recently issued reports on the company. Oppenheimer started coverage on Ocugen in a research note on Wednesday, March 11th. They set an "outperform" rating and a $10.00 price objective on the stock. Chardan Capital reiterated a "buy" rating and issued a $7.00 target price on shares of Ocugen in a research note on Wednesday, March 25th. Canaccord Genuity Group started coverage on Ocugen in a research note on Tuesday, March 17th. They issued a "buy" rating and a $12.00 target price on the stock. Wall Street Zen cut Ocugen from a "hold" rating to a "sell" rating in a research note on Saturday, April 4th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Ocugen in a research note on Thursday, January 22nd.

Institutional Investors Weigh In On Ocugen

A number of hedge funds have recently added to or reduced their stakes in the stock. Cora Capital Advisors LLC lifted its stake in Ocugen by 27.5% in the fourth quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company's stock valued at $41,000 after buying an additional 6,500 shares during the last quarter. Jain Global LLC lifted its stake in Ocugen by 7.2% in the fourth quarter. Jain Global LLC now owns 114,690 shares of the company's stock valued at $155,000 after buying an additional 7,686 shares during the last quarter. Lanham O Dell & Company Inc. raised its stake in shares of Ocugen by 7.7% during the third quarter. Lanham O Dell & Company Inc. now owns 140,000 shares of the company's stock valued at $228,000 after purchasing an additional 10,000 shares in the last quarter. Procyon Advisors LLC raised its stake in shares of Ocugen by 5.5% during the third quarter. Procyon Advisors LLC now owns 211,100 shares of the company's stock valued at $344,000 after purchasing an additional 11,000 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of Ocugen by 56.7% during the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company's stock valued at $36,000 after purchasing an additional 13,326 shares in the last quarter. 10.27% of the stock is currently owned by institutional investors.

Ocugen Stock Performance

Shares of OCGN opened at $1.76 on Friday. The business's fifty day moving average price is $1.79 and its 200 day moving average price is $1.58. Ocugen has a 12-month low of $0.64 and a 12-month high of $2.73. The stock has a market capitalization of $577.10 million, a PE ratio of -7.65 and a beta of 2.80. The company has a debt-to-equity ratio of 8.04, a current ratio of 1.06 and a quick ratio of 1.06.

Ocugen (NASDAQ:OCGN - Get Free Report) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06). Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18%.The firm had revenue of ($0.19) million for the quarter, compared to analysts' expectations of $0.86 million. Equities research analysts forecast that Ocugen will post -0.2 EPS for the current year.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.